A current review of the cutaneous manifestations of renal disease

Journal of Cutaneous Pathology

Volumn 30, Issue 9, 2003, Pages 527-538

  Abdelbaqi Salhab, Maisoun ^a   Shalhub, Sherene ^a   Morgan, Michael B ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BULLOUS SKIN DISEASE; CLINICAL FEATURE; COLLAGEN DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; ELASTOSIS PERFORANS SERPIGINOSA; FOLLICULITIS; HEMODIALYSIS PATIENT; HISTOPATHOLOGY; HUMAN; ICHTHYOSIS; KIDNEY DISEASE; KIDNEY FAILURE; KYRLE DISEASE; NAIL DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PERFORATING DISORDER OF UREMIA; PIGMENT DISORDER; PORPHYRIA CUTANEA TARDA; PREVALENCE; PRURITUS; REVIEW; SKIN CALCIFICATION; SKIN DISEASE; SKIN MANIFESTATION; SKIN PIGMENTATION; UREMIA; XEROSIS;

HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; SKIN DISEASES; UREMIA;

EID: 0141889753     PISSN: 03036987     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0560.2003.00109.x     Document Type: Review

References (87)

1. Nunley JR. Dermatologic manifestations of renal disease. eMed J 2002: topic 550 [Online].
2. Pico MR, Lugo-Somolinos A, Sanchez JL, Burgos-Calderon R. Cutaneous alterations in patients with chronic renal failure. Int J Dermatol 1992; 31 (12): 860.
3. Tercedor J, Lopez-Hernandez B, Rodenas JM, Delgado-Rodriguez M, Cerezo S, Serrano-Ortega S. Multivariate analysis of cutaneous markers of aging in chronic hemodialyzed patients. Int J Dermatol 1995; 34 (8): 546.
4. Lundin AP, Fani K, Berlyne GM, Friedman EA. Dermal angiopathy in hemodialysis patients: the effect of time. Kidney Int 1995; 47 (6): 1775.
5. Ponticelli C, Bencini PL. Uremic pruritus: a review. Nephron 1992; 60 (1): 1.
6. Stahle-Backdahl M, Hagermark O, Lins LE, Pruritus in patients on maintenance hemodialysis. Acta Med Scand 1988; 224 (1): 55.
7. Gilchrest BA, Stern RS, Steinman TI, Brown RS, Arndt KA, Anderson WW. Clinical features of pruritus among patients undergoing maintenance hemodialysis. Arch Dermatol 1982; 118 (3): 154.
8. Guyton AC. Textbook of medical physiology, 8th edn. New York: Thomson Publishing International, 1991.
9. Keele CA. Chemical causes of pain and itch. Annu Rev Med 1970; 21: 67.
10. Balaskas EV, Uldall RP. Erythropoietin treatment does not improve uremic pruritus. Perit Dial Int 1992; 12 (3): 330.
11. Tapia L. Pruritus on hemodialysis. Int J Dermatol 1979; 18 (3): 217.
12. Massry SG, Popovtzer MM, Coburn JW, Makoff DL, Maxwell MH, Kleeman CR. Intractable pruritus as a manifestation of secondary hyperparathyroidism in uremia. Disappearance of itching after subtotal parathyroidectomy. N Engl J Med 1968; 279 (13): 697.
13. Hampers CL, Katz AI, Wilson RE, Merrill JP. Disappearance of 'uremic' itching after subtotal parathyroidectomy. N Engl J Med 1968; 279 (13): 695.
14. Graf H, Kovarik J, Stummvoll HK, Wolf A. Disappearance of uraemic pruritus after lowering dialysate magnesium concentration. Br Med J 1979; 2 (6203): 1478.
15. Neiman RS, Bischel MD, Lukes RJ. Uraemia and mast-cell proliferation. Lancet 1972; 1 (7757): 959.
16. Matsumoto M, Ichimaru K, Horie A. Pruritus and mast cell proliferation of the skin in end stage renal failure. Clin Nephrol 1985; 23 (6): 285.
17. Stockenhuber F, Sunder-Plassmann G, Balcke P. Increased plasma histamine levels in chronic renal failure. N Engl J Med 1987; 317 (6): 386.
18. Stahle-Backdahl M. Uremic pruritus. Clinical and experimental studies. Acta Derm Venereol Suppl (Stockh) 1989; 145: 1.
19. Anderson CK. Asteatotic eczema. eMed J 2002: 538 [Online].
20. Park TH, Park CH, Ha SK, et al. Dry skin (xerosis) in patients undergoing maintenance haemodialysis: the role of decreased sweating of the eccrine sweat gland. Nephrol Dial Transplant 1995; 10 (12): 2269.
21. Griffon-Euvrard S, Bustamante R, Thiovolet J. Skin manifestations in patients with renal chronic renal failure on regular hemodyalysis. Med Ibero Lat Am 1976; 4 (6): 401.
22. Smith AG, Shuster S, Thody AJ, Alvarez-Ude F, Kerr DN. Role of the kidney in regulating plasma immunoreactive beta-melanocyte-stimulating hormone. Br Med J 1976; 1 (6014): 874.
23. Smith AG, Shuster S, Comaish JS, et al. Plasma immunoreactive beta-melanocyte-stimulating hormone and skin pigmentation in chronic renal failure. Br Med J 1975; 1 (5959): 658.
24. Kint A, Bussels L, Fernandes M, Ringoir S. Skin and nail disorders in relation to chronic renal failure. Acta Derm Venereol 1974; 54 (2): 137.
25. Lubach D, Strubbe J, Schmidt J. The 'half and half nail' phenomenon in chronic hemodialysis patients. Dermatologica 1982; 164 (5): 350.
26. Stewart WK, Raffle EJ. Brown nail-bed arcs and chronic renal disease. Br Med J 1972; 1 (803): 784.
27. Lever WF. Lever's histopatahology of the skin, 8th edn. Philadelphia: Lippincott-Raven, 1997.
28. Detlefs RL, Goette DK. Collagenome perforant verruciforme. Arch Dermatol 1986; 122 (9): 1044.
29. Rapini RP, Herbert AA, Drucker CR. Acquired perforating dermatosis. Evidence for combined transepidermal elimination of both collagen and elastic fibers. Arch Dermatol 1989; 125 (8): 1074.
30. Patterson JW. The perforating disorders. J Am Acad Dermatol 1984; 10 (4): 561.
31. Hood AF, Hardegen GL, Zarate AR, Nigra TP, Gelfand MC. Kyrle's disease in patients with chronic renal failure. Arch Dermatol 1982; 118 (2): 85.
32. Morton CA, Henderson IS, Jones MC, Lowe JG. Acquired perforating dermatosis in a British dialysis population. Br J Dermatol 1996; 135 (5): 671.
33. Mehregan AH, Schwartz OD, Livingood CS. Reactive perforating collagenosis. Arch Dermatol 1967; 96 (3): 277.
34. Mehregan AH. Perforating dermatoses: a clinicopathologic review. Int J Dermatol 1977; 16 (1): 19.
35. Bovenmyer DA. Reactive perforating collagenosis. Experimental production of the lesion. Arch Dermatol 1970; 102 (3): 313.
36. Kanan MW. Familial reactive perforating collagenosis and intolerance to cold. Br J Dermatol 1974; 91 (4): 405.
37. Poliak SC, Lebwohl MG, Parris A, Prioleau PG. Reactive perforating collagenosis associated with diabetes mellitus. N Engl J Med 1982; 306 (2): 81.
38. Zelger B, Hintner H, Aubock J, Fritsch PO. Acquired perforating dermatosis. Transepidermal elimination of DNA material and possible role of leukocytes in pathogenesis. Arch Dermatol 1991; 127 (5): 695.
39. Morgan MB, Truitt CA, Taira J, Somach S, Pitha JV, Everett MA. Fibronectin and the extracellular matrix in the perforating disorders of the skin. Am J Dermatopathol 1998; 20 (2): 147.
40. Haftek M, Euvrard S, Kanitakis J, Delawari E, Schmitt D. Acquired perforating dermatosis of diabetes mellitus and renal failure: further ultrastructural clues to its pathogenesis. J Cutan Pathol 1993; 20 (4): 350.
41. Hurwitz RM. The evolution of perforating folliculitis in patients with chronic renal failure. Am J Dermatopathol 1985; 7 (3): 231.
42. Robinson-Bostom L, DiGiovanna JJ. Cutaneous manifestations of end-stage renal disease. J Am Acad Dermatol 2000; 43 (6): 975.
43. Edwards RB, Jaffe W, Arrowsmith J, Henderson HP. Calciphylaxis: a rare limb and life threatening cause of ischaemic skin necrosis and ulceration. Br J Plast Surg 2000; 53 (3): 253.
44. Angelis M, Wong LL, Myers SA, Wong LM. Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery 1997; 122 (6): 1083.
45. Selye H, Goldie I, Strebel R. Calciphylaxis in relation to calcification in periarticular tissues. Clin Orthop 1963; 28: 181.
46. Gipstein RM, Coburn JW, Adams DA, et al. Calciphylaxis in man. A syndrome of tissue necrosis and vascular calcification in 11 patients with chronic renal failure. Arch Intern Med 1976; 136 (11): 1273.
47. Llach F, Velasquez FF. Secondary hyperparathyroidism in chronic renal failure: pathogenic and clinical aspects. Am J Kidney Dis 2001; 38 (5 Suppl. 5): S20.
48. Goodman WG. Vascular calcification in chronic renal failure. Lancet 2001; 358 (9288): 1115.
49. Goldsmith DJ, Black MM. Skin disorders in the setting of renal failure: invited editorial. J Eur Acad Dermatol Venereol 2001; 15 (5): 392.
50. Kang AS, McCarthy JT, Rowland C, Farley DR, van Heerden JA. Is calciphylaxis best treated surgically or medically? Surgery 2000; 128 (6): 967.
51. Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int 2002; 61 (6): 2210.
52. Kent RB, III, Lyerly RT. Systemic Calciphylaxis. South Med J 1994; 87 (2): 278.
53. Hafner J, Keusch G, Wahl C, Burg G. Calciphylaxis: a syndrome of skin necrosis and acral gangrene in chronic renal failure. Vasa 1998; 27 (3): 137.
54. Russell R, Brookshire MA, Zekonis M, Moe SM. Distal calcific uremic arteriolopathy in a hemodialysis patient responds to lowering of Ca X P product and aggressive wound care. Clin Nephrol 2002; 58 (3): 238.
55. Oh DH, Eulau D, Tokugawa DA, McGuire JS, Kohler S. Five cases of calciphylaxis and a review of the literature. J Am Acad Dermatol 1999; 40 (6 Part 1): 979.
56. Budisavljevic MN, Cheek D, Ploth DW. Calciphylaxis in chronic renal failure. J Am Soc Nephrol 1996; 7 (7): 978.
57. Coates T, Kirkland GS, Dymock RB, et al. Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis 1998; 32 (3): 384.
58. Adrogue HJ, Frazier MR, Zeluff B, Suki WN. Systemic Calciphylaxis revisited. Am J Nephrol 1981; 1 (3): 177.
59. Piccoli GB, Quaglia M, Quaglino P, et al. Acute digital gangrene in a long-term dialysis patient - a diagnostic challenge. Med Sci Monit 2002; 8 (11): CS83.
60. Jacobsohn HA, Jenkins PG, Jacobsohn KM. Penile calciphylaxis. Urology 2002; 60 (2): 344.
61. Wilmer WA, Magro CM. Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment. Semin Dial 2002; 15 (3): 172.
62. Hafner J, Keusch G, Wahl C, et al. Uremic small-artery disease with medial calcification and intimal hyperplasia (so-called calciphylaxis): a complication of chronic renal failure and benefit from parathyroidectomy. J Am Acad Dermatol 1995; 33 (6): 954.
63. Mehta RL, Scott G, Sloand JA, Francis CW. Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis. Am J Med 1990; 88 (3): 252.
64. Mazhar AR, Johnson RJ, Gillen D, et al. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 2001; 60 (1): 324.
65. Essary LR, Wick MR. Cutaneous calciphylaxis. An underrecognized clinicopathologic entity. Am J Clin Pathol 2000; 113 (2): 280.
66. Gilchrest B, Rowe JW, Mihm MC, Jr. Bullous dermatosis of hemodialysis. Ann Intern Med 1975; 83 (4): 480.
67. Day RS, Eales L. Porphyrins in chronic renal failure. Nephron 1980; 26 (2): 90.
68. Keczkes K, Farr M. Bullous dermatosis of chronic renal failure. Br J Dermatol 1976; 95 (5): 541.
69. Korting GW. Porphyria cutanea tarda-like aspects in 2 prolonged hemodialysis patients. Dermatologica 1975; 150 (1): 58.
70. Poh-Fitzpatrick MB, Masullo AS, Grossman ME. Porphyria cutanea tarda associated with chronic renal disease and hemodialysis. Arch Dermatol 1980; 116 (2): 191.
71. Wanic-Kossowska M, Furmanowska A, Pawliczak E, et al. Dermatosis bullosa in patient with chronic renal failure under hemodialysis treatment - case report. Pol Arch Med 2002; 108 (1): 671.
72. Pohfitzpatrick MB, Masullo AS, Grossman ME. Porphyria cutanea-tarda associated with chronic renal-disease and hemodialysis. Arch Dermatol 1980; 116 (2): 191.
73. Green JJ, Manders SM. Pseudoporphyria. J Am Acad Dermatol 2001; 44 (1): 100.
74. Glynne P, Deacon A, Goldsmith D, Pusey C, Clutterbuck E. Bullous dermatoses in end-stage renal failure: Porphyria or pseudoporphyria? Am J Kidney Dis 1999; 34 (1): 155.
75. Bickers DR, Pathak MA, Lim HW. Fitzpatrick's dermatology in general medicine, 5th edn. New York: McGraw Hill, 1999; 1766.
76. Schanbacher CF, Vanness ER, Daoud MS, Tefferi A, Su WP. Pseudoporphyria: a clinical and biochemical study of 20 patients. Mayo Clin Proc 2001; 76 (5): 488.
77. Maynard B, Peters MS. Histologic and immunofluorescence study of cutaneous porphyrias. J Cutan Pathol 1992; 19 (1): 40.
78. Gafter U, Mamet R, Korzets A, Malachi T, Schoenfeld N. Bullous dermatosis of end-stage renal disease: a possible association between abnormal porphyrin metabolism and aluminium. Nephrol Dial Transplant 1996; 11 (9): 1787.
79. LichtensteinJR, Babb EJ, Felsher BF. Porphyria cutanea tarda (PCT) in a patient with chronic renal failure on haemodialysis. Br J Dermatol 1981; 104 (5): 575.
80. Guolo M, Stella AM, Melito V, Parera V, Del CBA. Altered 5-aminolevulinic acid metabolism leading to pseudoporphyria in hemodialysed patients. Int J Biochem Cell Biol 1996; 28 (3): 311.
81. Breier F, Feldmann R, Pelzl M, Gschnait F. Pseudoporphyria cutanea tarda induced by furosemide in a patient undergoing peritoneal dialysis. Dermatology 1998; 197 (3): 271.
82. Tercedor J, Lopez HB, Rodenas JM. Bullous dermatosis of end-stage renal disease and aluminium. Nephrol Dial Transplant 1997; 12 (5): 1083.
83. Harvey E, Bell CH, Paller AS, et al. Pseudoporphyria cutanea tarda: two case reports on children receiving peritoneal dialysis and erythropoietin therapy. J Pediatr 1992; 121 (5 Part 1): 749.
84. Vadoud-Seyedi J, de Dobbeleer G, Simonart T. Treatment of haemodialysis-associated pseudoporphyria with N-acetylcysteine: report of two cases. Br J Dermatol 2000; 142 (3): 580.
85. Dabski C, Beutner EH. Studies of laminin and type IV collagen in blisters of porphyria cutanea tarda and drug-induced pseudoporphyria. J Am Acad Dermatol 1991; 25 (1 Part 1): 28.
86. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356 (9234): 1000.
87. Cowper SE, Su LD, BhawanJ, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001; 23 (5): 383.